Category: Covid-19 Vaccine

CORNING, NY (WETM) While the coronavirus continues to infect people around the globe, scientists are working to develop a vaccine, including a research team in Corning, NY.

The Corning Center for Clinical Research, an affiliate of Smith Allergy & Asthma Specialists of Central New York, enters the third of four phases in a trail to develop the vaccine in the first quarter of 2021.

The expected date for the vaccine cannot be revealed at this time due to confidentiality agreements with a nationally recognized pharmaceutical company, according to Dr. Christopher Smith Board-certified Allergy and Immunologist,

Smith says that he knows of other studies that are entering the third phase of their trail as early as this year.

Smith had 24-years of experience working on clinical research and has worked with all of the major pharmaceutical companies on a national and international scale.

I feel like this is the Super Bowl in terms of research, said Smith. Not that stuff that weve done previously didnt count, but this has such a relevance and importance to whats going on right now, its a different level.

The rest is here:

COVID-19 vaccine enters phase three in the Twin Tiers - WETM - MyTwinTiers.com

Director of the AstraZeneca Oncology Research and Development area, Josep Baselga

The distribution of the vaccine against COVID-19 could be done in advanced phase at the end of March 2021, according to estimates by the pharmaceutical company AstraZeneca, in charge of supplying the European Union (EU) with 300 million doses.

This was indicated this Monday, November 2nd, by the director of the AstraZeneca Oncology Research and Development area, Josep Baselga, who estimates that by the beginning of next year the pharmaceutical company will have about three billion vaccines that he trusts will be verified as effective.

The complicated thing will be to design how to distribute them given the demand that will exist, so Balsega estimates that until the end of the first quarter of 2021 the vaccines (if they work), would not be in the advanced distribution phase.

AstraZeneca expects that before the end of the year one, two or three of the four vaccines it is experimenting with will start to give good results.

In the case of this companys vaccines, the forecast is that two doses will be applied: the second 28 days after the first.

Right now there are 175 different vaccines in the world that are being worked on, 35 of them in clinical trials with patients, and 10 in their final verification phase, explained Balsega in radio statements.

The vaccine will help, but it is not the only solution, he said and recalled that AstraZeneca is also developing a treatment for monoclonal antibodies, with which antibodies from people who have passed the virus to potential patients would be applied.

There are 16 of these treatments in development and one in particular that is considered exceptionally good.

However, he was confident that after a winter that will be horrible next summer will be relatively normal, and argued that those who do not want to be vaccinated should not be forced to do so, because in his opinion this is a principle of individual freedom that is undeniable .

The Yucatan TimesNewsroom

comments

Read the rest here:

AstraZeneca expects to distribute COVID-19 vaccine by the end of March - The Yucatan Times

Why do I have to complete a CAPTCHA?

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

Another way to prevent getting this page in the future is to use Privacy Pass. You may need to download version 2.0 now from the Firefox Add-ons Store.

Read the original here:

COVID-19 Vaccination Should Not Be Contraindicated For Women Who Are Pregnant, Breastfeeding - Pink Sheet

Ethiopian Cargo & Logistics Servicesannounced its readiness with all required capabilities for the distribution of potential COVID-19 vaccine across Africa and the rest of the world.

Ethiopian Cargo & Logistics Services was instrumental in facilitating the flow of medical supplies including PPEs across the globe in support of the fight against the COVID-19 pandemic by deploying its state-of-the-art cargo terminal, which is the largest in Africa with annual capacity of around one million tons and compartmentalized temperature controlled cold storage facilities.

Commenting on Ethiopians preparation for the vaccine distribution, Ethiopian Group CEO Tewolde GebreMariam remarked, Ethiopian Pharma Wing will repeat its remarkable and globally recognized success in leading the fast delivery of PPE few months ago with similar delivery speed, professional handling and maintaining the cool chain during the forthcoming global distribution of the COVID-19 Vaccine. We are the major cargo partners of WHO, WFP donor governments and philanthropists in facilitating the flow of essential medical supplies owing to our massive cargo facility including our Pharma Wing, our large dedicated freighter fleet and well trained manpower. As the world prepares to welcome COVID-19 vaccine, We will be at the forefront to further discharge our responsibility in the distribution of the vaccine across the globe.

Equipped with different climate chambers ranging between -23OC to 25OC covering an area of 54,000m2, dedicated cool dollies, dedicated pharma team, lease/handling of Envirotainer & DoKaSCH-TS active containers, real-time temperature monitoring system and fully temperature controlled operation, the Pharma Wing of Ethiopian Cargo & Logistics Services is best suited for handling of pharmaceuticals and all types medical supplies. Additionally, leveraging the naturally air-conditioned weather of its home base Addis Ababa, Ethiopian guarantees safe and seamless cool chain logistics for handling temperature sensitive healthcare products.

It is to be recalled that Ethiopian demonstrated remarkable agility in its response to the increased cargo demand in the wake of the pandemic by reconfiguring around 25 passenger aircraft into freighters using its own internal MRO capabilities besides deploying all its 12 dedicated cargo aircraft.

WFP made Addis Ababa cargo terminal a distribution hub for all humanitarian aids considering the industry standard resources and capabilities of Ethiopian Cargo & Logistics Services and the super-efficient service delivery demonstrated during the distribution of medical supplies provided by different donors including Jack Ma Foundation, WHO and the Chinese Government among others. Since the COVID-19 outbreak, Ethiopian operated over 360 charter flights to transport PPEs over 100 countries across 5 continents.

Read the original here:

Ethiopian Pharma Wing Ready to Distribute the COVID-19 Vaccine - American Journal of Transportation

Even before the word pandemic entered daily conversation, Johnson & Johnson scientists were digging into the genetic sequence of the novel coronavirus and assessing vaccine candidates.

That was January. At the same time, J&J communications exec Seema Kumar and her team were trying to figure out how to let the world know.

The ambitious idea they came up witha live weekly video series with multiple guests,hosted by journalist Lisa Linglaunched in April as The Road to a Vaccine and continues today. It airs every Tuesday at noon ET on Facebook, Twitter, LinkedIn and JNJ.com.

How technologies are transforming high volume injections - essential enablers for patient outcomes

Therapies requiring high volume injections are becoming more common across a broad range of therapeutic areas. This webinar will explore why adherence, safety and quality of life are important for patients, and how these key enablers contribute towards positive outcomes. We will also discuss existing challenges, such as drug development, regulatory, patient accessibility, and how device technologies can further improve patient outcomes. Register Today!

Even though we still didnt know where the journey would take us, the moment we began to work on a vaccine we felt we had to bring our audience along with us, Kumar, global head of J&Js office of innovation, global health and scientific engagement, said Friday during Fierce Pharma Marketings Digital Pharma Innovation Week.

RELATED: J&J tracks the path to a COVID-19 vaccine in new online news series

The behind-the-scenes show featuresJ&J researchers and execs such as Chief Scientific Officer Paul Stoffels, M.D., but also spotlights public health officials like Johns Hopkins University's Tom Inglesby, M.D., and even well-known advocates like actor Laverne Cox.

While it began as an exploration of how a vaccine would be created, the show has also taken on COVID-19-related topics such as mental health, school reopenings and racial disparities.

At its core is science, Kumar saidfeeding peoples hunger for knowledge, especially during the early days of the pandemicbut also demystifying the company's processes and, in doing so, increasing transparency that canhelpbuild trust.

RELATED: J&J, Pfizer comms chiefs talk vaccine pledge, politics, inequality and getting to a 'better normal'

People are interested in science. We just need to make it relevant and understandable and relatable, she said. "I think we need to take science from being available to a privileged few who speak that language to making it accessible for all.

Public engagement with the series backs that upmore than l00 millionviews from people in 120 countries around the world since it began. For Kumar, even more affirming are the comments and feedback from viewers who've thanked J&J for "being honest or noted that the videos increased their trust in science.

At the end of the day, science is about society, and society has to understand the processes of science, she said.

Read more:

J&J's weekly vaccine series, with 100M views to its credit, finds success demystifying science - FiercePharma

Nov. 3 (UPI) -- U.S. drugmaker Pfizer will use its own distribution network for its COVID-19 vaccine rather than a going through the U.S. government's designated coordinator, a company official has said.

The pharma company will seek to ensure "end-to-end visibility and control" in its distribution of millions of doses of its vaccine, once it's approved for use in the United States, according to Pfizer Vice President for Biopharma Global Supply Chain Tanya Alcorn.

Alcorn said rather than tap healthcare logistics provider McKesson, as recommended by federal regulators, the serious challenges involved in doling out a vaccine requires Pfizer to keep tight control of distribution.

She made the comments during a webinar with the U.S. Chamber of Commerce webinar.

"We value McKesson... but early on we set up a distribution model where we would ship direct from our U.S. manufacturing facility and our U.S. distribution center direct to the points of use," Alcorn added.

Under the government's Operation Warp Speed, drugmakers are expected to deliver vaccines to McKesson centers, which in turn will coordinate distribution to hospitals and other vaccination points.

Alcorn said Pfizer is instead developing its own plan, in coordination with the Centers for Disease Control and Prevention.

"We're working with trusted [logistics] partners," she said. "That will allow us to have end-to-end visibility and control."

Pfizer said last week its late-stage human clinical trial for its BNT162 vaccine is close to full enrollment, with more than 42,000 participants. It has partnered with German drugmaker BioNTech to develop the vaccine, which is one of several in development worldwide.

The rest is here:

Pfizer to bypass gov't, use its own network to ship COVID-19 vaccine - UPI News

Pharmaceutical company Moderna is aiming to distribute its COVID-19 vaccine globally, reportedly already accepting $1.1 billion in deposits from governments around the world looking to secure doses of the vaccine, CNBC reports.

The firm revealed this in its third quarter earnings report, saying that it has been engaging in negotiations with the World Health Organization (WHO) and its vaccine distribution cohort COVAX. Moderna and the agency are working on a tiered pricing proposal for the drug, called mRNA-1273, to help it be distributed equitably throughout the world.

Moderna has already secured supply agreements with North America, the Middle East and other regions.

HOW TO GET READY FOR THE THIRD WAVE OF CORONAVIRUS AND THE WINTER SEASON

WEARING MASKS COULD SAVE MORE THAN 100,000 LIVES IN THE NEXT FEW MONTHS: NEW STUDY

SMART SENSORS COULD BE A HIGH-TECH SOLUTION TO SOCIAL DISTANCING IN OFFICES

US RECORDS SECOND-HIGHEST SINGLE-DAY RISE IN COVID-19 INFECTIONS SINCE PANDEMIC BEGAN

We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world, Moderna CEO Stphane Bancel said in a press release. Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273.

The vaccine candidate is made up of messenger RNA, which may help the body launch an immune reaction when it detects the virus.

Moderna has been one of the frontrunners in the race to develop a COVID-19 vaccine. The drug manufacturer has been receiving funding from the White House as part of the Trump Administrations Operation Warp Speed plan.

MRNA-1273 is in the final stage three clinical trials. As of last week, CNBC notes that more than 25,650 volunteers had received the second dose of the companys drug.

In August, the company reportedly said that it would charge somewhere between $32 and $37 per dose for mRNA-1273 for some customers to make it affordable.

When the vaccine would be widely available was not mentioned. Public health officials like Anthony Fauci have repeatedly said that a vaccine wont be widely available until mid-2021, but that data showcasing an effective and safe vaccine will be ready in December.

Earlier in October, Bancel confirmed that the Moderna vaccine will be ready to be widely distributed around the late first quarter to the early second quarter of 2021.

He also noted that the company would not file for the U.S. Food and Drug Administrations Emergency Use Approval until Nov. 25 at the earliest.

KANSASS COVID-19 POSITIVITY RATE SURPASSES 20 PERCENT

MOST VOTERS BELIEVE THE CORONAVIRUS IS OUT OF CONTROL IN THE US, POLL SAYS

CDC STRONGLY RECOMMENDS ALL PASSENGERS ON PLANES, TRAINS, BUSES WEAR MASKS TO SLOW SPREAD OF COVID-19

THE COMING WEEKS WILL BE DARKEST OF THE ENTIRE PANDEMIC, INFECTIOUS DISEASES EXPERT SAYS

Visit link:

Moderna is preparing the global launch of its COVID-19 vaccine | TheHill - The Hill

Every week, The American Journal of Managed Care recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Every week, The American Journal of Managed Carerecaps the top managed care news of the week.

This week, the top managed care news included updates on coronavirus disease 2019 therapies and vaccine candidates; a discussion on keeping physicians independent through value-based care; an overview of the 2020 Community Oncology Alliance Virtual Payer Exchange Summit.

Listen above or through one of these podcast services:

iTunesTuneInStitcherSpotify

Originally posted here:

Podcast: This Week in Managed CareAn Update on COVID-19 Vaccine and Therapies and Other Health News - AJMC.com Managed Markets Network

A handful of drone-delivery startups want to help transport Covid-19 vaccines from distribution facilities to health centers, vying for a logistical role in what is likely to be a sprawling and complex undertaking.

Several of these businesses recently have entered into medical delivery partnerships with drug companies and retailersincluding Merck & Co. and Walmart Inc. that could help position them to take part in the high-profile effort to distribute Covid-19 vaccines.

Meanwhile,...

Go here to read the rest:

Drone Startups Aim to Carve Out Role in Delivery of Potential Covid-19 Vaccine - The Wall Street Journal

Would you sign up for a vaccine trial? One Lancaster woman shares her experience with the DNA vaccine trial from Penn Medicine.

LANCASTER, Pa. A Lancaster mother is doing her part amid the COVID-19 pandemic by participating in a clinical trial for a COVID-19 vaccine. Stella Sexton, 41, signed up for the INOVIO COVID-19 Vaccine Phase 1 Clinical Trial by Penn Medicine and the Perelman School of Medicine.

Sexton said she stumbled up the trials need for volunteers on the Lancaster Countys website at the height of the coronavirus pandemic.

This was back in May and of course I had been home with my kids and trying to get them through school, Sexton explained. I was shopping for my elderly relatives and I was trying to keep everybody going. I just thought Gosh, we need to get a vaccine to end this.

The healthy mother of two felt she had a chance to make a difference. She signed up for the DNA vaccine trial and received her first dose on June 8. Sexton received a booster shot one month later.

The interesting thing about this vaccine is that they have basically stripped those little spikes off the [virus] so it doesnt contain the whole virus. It cant make me contagious and it cant make me sick, Sexton added. The goal is to see what my immune system does just with the vaccine.

After injecting the vaccine, nurses use a device that delivers electrical pulses to your skin, said Sexton, to open up the pores of your skin cells and allow the DNA to get into your skin.

The global coalition of collaborators and partners assembled by Inovio includes the scientific team at the Wistar Institute of the University of Pennsylvania, whose contributions included key research. Inovio Pharmaceuticals received a $5 million grant from the Bill & Melinda Gates Foundation to accelerate the testing of the CELLECTRA 3PSP device to deliver the vaccine.

The DNA vaccine trial lasts 52 weeks. Sexton has routine bloodwork done and has been documenting the process on her Instagram page, @stellavaccinates. She is sharing her journey with the world to educate people who may be curious about a vaccine.

I know it seems fast and that they are rushing it, but I think people should understand that ever since SARS-CoV-1 there was all this research that happened into coronavirus vaccines. That research is what were benefitting from now, Sexton said.

The hope is that future generations will benefit from the research scientists are learning todayall because of people like Sexton.

To me, it felt like something I had to do for my family, something I had to do for my grandparents and my older relatives, but also I really feel that its a patriotic duty, added Sexton.

Other clinical trials for a COVID-19 vaccine are currently enrolling volunteers. If you are interested in participating, visitcoronaviruspreventionnetwork.org for more information.

See the rest here:

What's it like to take part in a COVID-19 vaccine trial? A Lancaster mother shares her journey - FOX43.com